Pharmacokinetic crossover trials on GelShield Extended-Release Metformin gut tolerability, topical Diclofenac patch RCTs for targeted joint relief without GI bleeding, and Phase 3 biologic clearance trials in psoriasis and autoimmune disease. Explore 546 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Of 31 participants screened, 22 were randomized; 1 placebo-assigned participant did not meet the NRS ≥5 criterion and was excluded, leaving 21 for analysis (IFT: 11; placebo: 10).
Patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups receiving vunakizumab show a favourable clinical response, regardless of achieving early response or not.
NTCP models for acute and late diarrhea and persistent GI toxicity after postoperative radiotherapy for cervical cancer included bowel V30Gy and V40Gy.
Although the primary endpoint was not met, the data provide important information on baricitinib for the treatment of children with JIA-U refractory to both MTX and bDMARDs.
In 387 subjects, among endoscopically active subjects (MES 2, 3), the CDS was lower in those achieving PMS symptomatic full symptom relief (83.8 vs 186.9, P < 0.0001).
Compared with conventional OST, the mini S-OST split dose showed excellent efficacy, comparable safety and tolerability, with less gastric injury (ClinicalTrial.gov identifier NCT06287606).
The combination of HESr and alfuzosin was significantly more effective than alfuzosin single-drug treatment in relieving LUTS, with greater benefits from Month 3 onward.
The results support the HYPO-RT-PC findings by showing similar morbidity between ultra-hypofractionated and standard radiotherapy.
The responder definitions were at least a 3-point improvement for PROMIS-PF, a 10% improvement for active ROM, and a 2-point improvement for the Worst Stiffness NRS.
In a difficult-to-treat population with OA, fasinumab 1 mg Q4W achieved clinically meaningful improvements by week 16 versus placebo and naproxen.
This meta-analysis suggests that elevated SIRI is associated with poorer OS and PFS in glioma patients, although this association was not consistently observed across all subgroups, particularly in European populations. These findings highlight the need for further validation with standardized cut-off values in diverse populations.
Pain and anxiety outcomes following cryotherapy did not differ significantly from those of the topical anesthetic agents, while treatment compliance was higher, suggesting that cryotherapy may be a promising non-pharmacological option, pending confirmation in non-inferiority trials. ClinicalTrials.gov NCT07198022.
RFX treatment reduced microbial richness and decreased the abundance of taxa typically enriched in advanced cirrhosis (e.g., Escherichia , Streptococcus , Veillonella ).
Xeligekimab provides rapid symptom resolution across all clinical dimensions, high and sustained achievement of treatment targets, and comprehensive restoration of quality of life.
These findings on the pharmacology of VOS underscore the importance of rapidly restoring key protective functions of the microbiome in patients with recurrent CDI to achieve durable prevention of recurrence, as observed in the...
These findings indicate that chronic kidney disease-associated severe itching intensity is linked to systemic inflammation, potentially through a neuroimmune crosstalk mechanism.
Upadacitinib effectively reduced pain in active RA and PsA, including in patients with AoI.
These results validate JSpADA as a disease activity measure for children with ERA and jPsA in a prospective clinical trial setting.
Responders additionally reported greater improvement from baseline than non-responders for measures of AA-related emotional symptoms, mental health, and work or activity limitations.
The microbiota-gut-brain axis is posited to modulate health-related quality of life, microbiome, and metabolome changes through immune, gastrointestinal, and central nervous system functions in patients with recurrent C.
This study utilizes data from a large clinical trial to establish a method with high specificity for exploring clonal engraftment from microbiota-based treatments to facilitate future how the body absorbs the medicine and how...
LPP is significantly associated with autoimmune disorders, thyroid diseases, and skin cancer.
Guselkumab, a fully human monoclonal antibody able to bind CD64 and simultaneously inhibit the IL-23p19 subunit, provided significantly higher rates of clinical improvement and significant inhibition of structural damage...
Carotegrast methyl appears most effective in patients with moderately active ulcerative colitis with low disease activity, with week 2 and beyond as an appropriate time point for assessing efficacy.
CONCLUSION: Our composite biomarker score showed a moderate cross-sectional correlation with mRSS and potentially complement mRSS in the assessment of skin activity.
Mixing lidocaine-epinephrine with ropivacaine significantly shortened the duration of pain-relieving by up to 5 h without affecting the sensory onset time.
These results confirm the effectiveness of eptinezumab in Japanese participants with CM to reduce the burden of migraine and improve the ability to undertake daily life activities.
CONCLUSIONS: The PFCSD is a novel, fit-for-purpose PRO measure evaluating key symptoms experienced by patients with FC aged 6 to 17 years.
Additionally, there was a significantly higher incidence of herpes simplex infections in eczema patients with target-selective JAK inhibitors, while no increased risk was observed with herpes zoster.
These findings confirm that AA is associated with a heightened risk of various immune-mediated conditions.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
